249 related articles for article (PubMed ID: 38339286)
1. PIM3 Kinase: A Promising Novel Target in Solid Cancers.
Atalay P; Ozpolat B
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339286
[TBL] [Abstract][Full Text] [Related]
2. A review on structure-function mechanism and signaling pathway of serine/threonine protein PIM kinases as a therapeutic target.
Rout AK; Dehury B; Parida SN; Rout SS; Jena R; Kaushik N; Kaushik NK; Pradhan SK; Sahoo CR; Singh AK; Arya M; Behera BK
Int J Biol Macromol; 2024 Jun; 270(Pt 1):132030. PubMed ID: 38704069
[TBL] [Abstract][Full Text] [Related]
3. PIM Kinase as an Executional Target in Cancer.
Zhang X; Song M; Kundu JK; Lee MH; Liu ZZ
J Cancer Prev; 2018 Sep; 23(3):109-116. PubMed ID: 30370255
[TBL] [Abstract][Full Text] [Related]
4. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.
Brault L; Gasser C; Bracher F; Huber K; Knapp S; Schwaller J
Haematologica; 2010 Jun; 95(6):1004-15. PubMed ID: 20145274
[TBL] [Abstract][Full Text] [Related]
5. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
[TBL] [Abstract][Full Text] [Related]
6. Targeting PIM kinases in cancer therapy: An update on pharmacological small-molecule inhibitors.
Chen S; Yang Y; Yuan Y; Bo Liu
Eur J Med Chem; 2024 Jan; 264():116016. PubMed ID: 38071792
[TBL] [Abstract][Full Text] [Related]
7. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
[TBL] [Abstract][Full Text] [Related]
8. Structure Guided Optimization, in Vitro Activity, and in Vivo Activity of Pan-PIM Kinase Inhibitors.
Burger MT; Han W; Lan J; Nishiguchi G; Bellamacina C; Lindval M; Atallah G; Ding Y; Mathur M; McBride C; Beans EL; Muller K; Tamez V; Zhang Y; Huh K; Feucht P; Zavorotinskaya T; Dai Y; Holash J; Castillo J; Langowski J; Wang Y; Chen MY; Garcia PD
ACS Med Chem Lett; 2013 Dec; 4(12):1193-7. PubMed ID: 24900629
[TBL] [Abstract][Full Text] [Related]
9. The PIM kinases in hematological cancers.
Alvarado Y; Giles FJ; Swords RT
Expert Rev Hematol; 2012 Feb; 5(1):81-96. PubMed ID: 22272708
[TBL] [Abstract][Full Text] [Related]
10. Targeting Pim kinases in hematological cancers: molecular and clinical review.
Bellon M; Nicot C
Mol Cancer; 2023 Jan; 22(1):18. PubMed ID: 36694243
[TBL] [Abstract][Full Text] [Related]
11. The PIM family of oncoproteins: small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets.
Saurabh K; Scherzer MT; Shah PP; Mims AS; Lockwood WW; Kraft AS; Beverly LJ
Oncotarget; 2014 Sep; 5(18):8503-14. PubMed ID: 25238262
[TBL] [Abstract][Full Text] [Related]
12. PIM Kinases in Multiple Myeloma.
Wu J; Chu E; Kang Y
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503111
[TBL] [Abstract][Full Text] [Related]
13. The serine-threonine kinase PIM3 is an aldosterone-regulated protein in the distal nephron.
Spirli A; Cheval L; Debonneville A; Penton D; Ronzaud C; Maillard M; Doucet A; Loffing J; Staub O
Physiol Rep; 2019 Aug; 7(15):e14177. PubMed ID: 31397090
[TBL] [Abstract][Full Text] [Related]
14. The role of PIM1/PIM2 kinases in tumors of the male reproductive system.
Jiménez-García MP; Lucena-Cacace A; Robles-Frías MJ; Narlik-Grassow M; Blanco-Aparicio C; Carnero A
Sci Rep; 2016 Nov; 6():38079. PubMed ID: 27901106
[TBL] [Abstract][Full Text] [Related]
15. PIM3 Promotes the Proliferation and Migration of Acute Myeloid Leukemia Cells.
Luo H; Sun R; Zheng Y; Huang J; Wang F; Long D; Wu Y
Onco Targets Ther; 2020; 13():6897-6905. PubMed ID: 32764981
[TBL] [Abstract][Full Text] [Related]
16. Proto-Oncogene Serine/Threonine Kinase PIM3 Promotes Cell Migration via Modulating Rho GTPase Signaling.
Dang Y; Jiang N; Wang H; Chen X; Gao Y; Zhang X; Qin G; Li Y; Chen R
J Proteome Res; 2020 Mar; 19(3):1298-1309. PubMed ID: 31994402
[TBL] [Abstract][Full Text] [Related]
17. PIM3 Functions as Oncogenic Factor and Promotes the Tumor Growth and Metastasis in Colorectal Cancer.
Qi Q; Pan Y; Han S; Liao H; Jiang Y; Shen J; Zhong L; Wang X; Chen J
Anat Rec (Hoboken); 2019 Sep; 302(9):1552-1560. PubMed ID: 30417983
[TBL] [Abstract][Full Text] [Related]
18. Using insights into Pim1 structure to design new anticancer drugs.
Schenone S; Tintori C; Botta M
Curr Pharm Des; 2010; 16(35):3964-78. PubMed ID: 21158732
[TBL] [Abstract][Full Text] [Related]
19. PIM3 kinase promotes tumor metastasis in hepatoblastoma by upregulating cell surface expression of chemokine receptor cxcr4.
Marayati R; Julson J; Bownes LV; Quinn CH; Stafman LL; Beierle AM; Markert HR; Hutchins SC; Stewart JE; Crossman DK; Hjelmeland AB; Mroczek-Musulman E; Beierle EA
Clin Exp Metastasis; 2022 Dec; 39(6):899-912. PubMed ID: 36315303
[TBL] [Abstract][Full Text] [Related]
20. The PIM family of serine/threonine kinases in cancer.
Narlik-Grassow M; Blanco-Aparicio C; Carnero A
Med Res Rev; 2014 Jan; 34(1):136-59. PubMed ID: 23576269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
